Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Study: Fat cells play key role in dangerous transformation of melanoma

Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells […]

Dr. Flaherty on the COLUMBUS Trial Updates in BRAF-Mutant Melanoma

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses an update on overall survival (OS) in COLUMBUS, a randomized phase III trial of encorafenib (Braftovi) plus binimetinib (Mektovi) versus vemurafenib (Zelboraf) or encorafenib in patients with BRAF V600-mutant melanoma.

Melanoma: Optimizing Selection of Adjuvant Therapy

Dirk Schadendorf, MD, PhD: I disagree. I think what we have to keep in mind that in stage III disease, with just the surgery we are curing, is in roughly one-third of the patients.

Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant Melanoma

Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses results from the 5-year analysis of the combination of dabrafenib and trametinib in patients with BRAF V600E-mutant melanoma.